Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757544 | 0.95 | GSR (0.48) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL9845047 | 0.95 | GSR (0.48) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL13059111 | 0.88 | OTC (0.51) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL448333 | 0.86 | OTC (0.53) | OTCDDAH1GSRNOS2NOS3 | |
| Tilarginine SCHEMBL12028766 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS2NOS3 | |
| Tilarginine SCHEMBL6370536 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS2NOS3 | |
| Tilarginine SCHEMBL315843 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL21089964 | 0.84 | OTC (0.51) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL24451312 | 0.83 | OTC (0.50) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL8730134 | 0.83 | NOD1 (0.52) | OTCDDAH1GSRNOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| EP-4598592-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | Owlstone Medical Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| CN-120152745-A | Compounds and their use for detecting diseases in exhaled breath of a subject | 奥斯通医疗有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEAGEN INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-08-08 | — | — | US | disclosed |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-07-25 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| EP-4103587-A1 | CORONA VIRUS VACCINE | Immunor AS (NO) | 2022-12-21 | — | — | EP | disclosed |
| EP-4074328-A1 | INTERMEDIATES OF CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seagen Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| EP-4043076-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GeneFrontier Corporation (JP) | 2022-08-17 | — | — | EP | disclosed |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220072146-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEAGEN INC (US) | 2022-03-10 | — | — | US | disclosed |
| US-9574190-B2 | Screening method for peptide binding to target molecule in pH-dependent manner | THE UNIVERSITY OF TOKYO (JP) | 2017-02-21 | — | — | US | disclosed |
| CN-1326785-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2001-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | OTC 955/4885DDAH1 679/4885GSR 2923/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | OTC 3651/4885DDAH1 3101/4885GSR 4749/4885 |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | OTC 2274/4885DDAH1 2586/4885GSR 1896/4885 |
| US-20220072146-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | OTC 1200/4885DDAH1 1163/4885GSR 1502/4885 |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | OTC 2659/4885DDAH1 3074/4885GSR 4646/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | OTC 1408/4885DDAH1 495/4885GSR 1876/4885 |
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | OTC 645/4885DDAH1 3208/4885GSR 869/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | OTC 2274/4885DDAH1 2586/4885GSR 1896/4885 |
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | OTC 1199/4885DDAH1 1166/4885GSR 1501/4885 |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | OTC 2274/4885DDAH1 2586/4885GSR 1896/4885 |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | OTC 2274/4885DDAH1 2586/4885GSR 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.